* 从药明生物2269.HK分拆上市的中国药明合联2268.HK周四早盘一度劲升8%，早市收高7.2%。
* 美国投行富瑞在报告中表示，将药明合联的目标价由41港元上调至60港元，以反映在手订单量的强劲增长和高可见度；该公司的新加坡生产基地将在2025年底开始生产。
* 药明合联今年迄今劲涨46.3%，同期恒生指数.HSI大幅上扬18.3%。
* 恒生香港上市生物科技指数.HSHKBIO早盘收涨4.1%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 田镧沁)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.